Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04774315 · ClinicalTrials.gov registry record · Phase 4
Molecular Endotypes of Chronic Idiopathic Urticaria
A Phase 4 study of Chronic Urticaria, Idiopathic, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04774315: Active Phase 4 study of Chronic Urticaria, Idiopathic, sponsored by University of Colorado, Denver.
NCT04774315 is a Phase 4 study of Chronic Urticaria, Idiopathic that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 15 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04774315, a Phase 4 study of Chronic Urticaria, Idiopathic, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study plans to learn more about why some people with Chronic Idiopathic Urticaria (CIU) respond to treatment with omalizumab (Xolair). It will test people before they receive treatment with omalizumab as part of standard of care, to see if there are differences in their blood and skin that can predict who responds to treatment.
Conditions Studied
Interventions
- DRUG Omalizumab
Study Locations (1)
Colorado
- University of Colorado Anschutz - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2025-03 |
| Phase | Phase 4 |
What the registry record for NCT04774315 still lists
NCT04774315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Chronic Urticaria, Idiopathic appearing as the primary indexed condition, and to 1 intervention - of which Omalizumab is the first listed.
NCT04774315 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT04774315 about?
NCT04774315 is a clinical study titled "Molecular Endotypes of Chronic Idiopathic Urticaria". This study plans to learn more about why some people with Chronic Idiopathic Urticaria (CIU) respond to treatment with omalizumab (Xolair). It will test people before they receive treatment with omalizumab as part of standard of care, to see if there are differences in their blood and skin that can ...
What is the current status of trial NCT04774315?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2022-01-01. Estimated completion is 2025-03.
What conditions does trial NCT04774315 study?
This clinical trial studies the following conditions: Chronic Urticaria, Idiopathic.
What interventions are being tested in trial NCT04774315?
The interventions under investigation include: Omalizumab (DRUG).
Who is sponsoring clinical trial NCT04774315?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04774315 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04774315's enrollment target sits among peer trials
15 1881st of 2000 higher than 100 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI